U.S. Legislative Shift Could Propel Canopy Growth's Strategic Ambitions

Bipartisan bill may allow Canopy Growth to list on major U.S. exchanges and consolidate its American assets, as the company reports improved financials and a path to profitability.

A bipartisan legislative proposal currently before the U.S. Congress has the potential to significantly accelerate Canopy Growth Corporation's long-term strategy for the American market. The introduction of the Capital Lending and Investment for Marijuana Businesses (CLIMB) Act could remove a major barrier for cannabis companies by permitting listings on major national exchanges, including the Nasdaq and the NYSE. This development aligns precisely with the corporate framework Canopy Growth has meticulously established for its U.S. operations.

Financial and Operational Standing Shows Improvement

As these potential regulatory changes unfold, Canopy Growth approaches this juncture with a notably strengthened financial foundation. For its third fiscal quarter of 2026, which concluded in December 2025, the company reported consolidated net revenue of 75 million CAD. Its cannabis segment contributed 52 million CAD of this total, marking a four percent increase compared to the same period the prior year.

The firm's net loss contracted by 49 percent year-over-year, while its adjusted EBITDA loss narrowed substantially to 3 million CAD. This performance represented the third consecutive quarter of sequential improvement. Management has reiterated that achieving a positive adjusted EBITDA by fiscal year 2027 remains a core objective. As of the quarter's end, Canopy Growth held 371 million CAD in cash and short-term investments, resulting in a net cash position of 146 million CAD.

Furthermore, the company has realized annualized savings of 29 million CAD since March 2025, exceeding its initial targets. Additional synergies of approximately 10 million CAD are anticipated within 18 months following the acquisition of MTL Cannabis.

The Mechanics and Impact of the Proposed CLIMB Act

The CLIMB Act was formally introduced this week by Representatives Guy Reschenthaler (R-PA) and Troy Carter (D-LA). Its provisions extend beyond simply allowing exchange listings. The legislation would also shield financial institutions, insurance providers, and advertising services from federal penalties for working with state-licensed cannabis businesses.

For Canopy Growth, this is not a peripheral political note but a potential catalyst for its specific corporate design. The company created its Canopy USA subsidiary as a strategic vehicle to hold economic interests in U.S. cannabis assets—such as the brands Jetty, Wana, and Acreage—without violating current Nasdaq listing rules. Should the CLIMB Act pass, it would enable Canopy USA to fully consolidate these interests and their revenues onto the parent company's financial statements.

This legislative effort runs parallel to a separate administrative review to reclassify cannabis from a Schedule I to a Schedule III substance under the Controlled Substances Act. In December, President Trump directed the Attorney General to expedite this process. A successful reclassification would additionally allow state-licensed cannabis operators to claim standard federal tax deductions, which are currently prohibited under IRS code 280E.

Challenges and Market Sentiment Persist

Despite these operational and potential regulatory advances, significant challenges remain. Over the trailing twelve-month period, the company's losses totaled 326.6 million CAD, with an operating cash outflow of 78.7 million CAD. Sustainable profitability has not yet been achieved.

Market sentiment reflects this ongoing uncertainty. The stock recently traded at 1.01 U.S. dollars. On the TSX, its 52-week range has spanned from 1.085 to 3.28 CAD. Short sellers continue to maintain positions, betting that the anticipated federal reclassification could ultimately fail—a tangible risk for as long as the political process in Washington remains unresolved.

Investors are awaiting the company's fourth-quarter and full fiscal year 2026 results, scheduled for release on May 29, 2026. This report will provide critical evidence on whether the recent operational progress is sustainable and how close the company is to reaching its goal of positive EBITDA.